Abstract:e19093 Background: No study has compared MPEs with matching tumor tissues and plasma DNA and clinical value of MPEs for advanced ADC patients with pleural effusions is not confirmed. This study aims to evaluate MPEs as surrogate of tissue for EGFR mutation detection, and the correlation with efficacy of EGFR-TKI (tyrosine kinase inhibitor) treatment. Methods: 297 MPE samples from advanced lung ADC patients were collected, in which 92 have matched tissues and 248 have matched plasma samples. EGFR (exon 19 deletion and exon 21 L858R) mutation was detected by denaturing high performance liquid chromatography (DHPLC). Results: EGFR mutation rate in MPE is 39.1% (116/297). Consistency of MPE supernatant and tissue was 87.0% (Kappa = 0.71), sensitivity and specificity was 92.6%, 84.6% separately. For patients with EGFR mutant MPE treated with EGFR-TKI, the objective response rate (ORR) (54.5% VS. 18.9%, p < 0.001), progression free survival (PFS) (8.9m vs. 3.0m, P < 0.001) and overall survival (OS) (24.0m vs. 17.5m, P = 0.022) was significantly higher compared with EGFR wild MPEs patients. In subgroup patients of whom MPEs obtained before EGFR-TKI treatment, patients with EGFR-mutant MPEs (n = 78) had greater advantages in TKI therapy, compared with the EGFR-wild ones (n = 91) (ORR: 55.1% vs. 19.8% in EGFR-wild group; DCR: 92.3% vs. 65.9%; P < 0.001). Compared to chemotherapy, EGFR-TKI could benefit EGFR-mutant group with higher ORR (56.1% vs. 16.7%, P = 0.001) and longer PFS (8.8m vs. 3.5m, P < 0.001). Further analysis showed patients with exon 19 deletion mutation in MPE could benefit from first-line EGFR-TKI followed second-line chemotherapy with a median OS of 31.5m VS 20.7m (P = 0.036) compared with those treated with first-line chemotherapy followed EGFR-TKI, while patients with exon 21 L858R mutation showed the opposite result. Conclusions: MPEs could be used as surrogate for tumor tissue to detect EGFR mutation. Lung ADC patients with EGFR mutation in MPEs could benefit from EGFR-TKI treatment. Patients with EGFR exon 19-deletion mutation in MPE may prioritize first-line EGFR-TKI followed chemotherapy.

Diagnostic Value of Pleural Effusion for the Detection of EGFR in NSCLC: a Meta-Analysis

Pleural Effusion As a Substitute for Tumor Tissue in Detecting EGFR/ALK Mutations in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Cytology Cell Blocks from Malignant Pleural Effusion Are Good Candidates for PD-L1 Detection in Advanced NSCLC Compared with Matched Histology Samples

Value of Malignant Pleural Effusion Supernatants (mpes) in Epidermal Growth Factor Receptor (EGFR) Mutation Detection of Patients with Advanced Lung Adenocarcinoma (ADC).

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Clinical value of the detection of EGFR gene mutations in pleural effusion cell blocks among patients with non-small-cell lung cancer

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Diagnostic Value Of Mutation-Specific Antibodies For Immunohistochemical Detection Of Epidermal Growth Factor Receptor Mutations In Non-Small Cell Lung Cancer: A Meta-Analysis

Comparative Study of EGFR Mutations Detected in Malignant Pleural Effusion, Plasma and Tumor Tissue in Patients with Adenocarcinoma of the Lung

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.

Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 with Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer

Carcinoembryonic Antigen in Pleural Effusion of Patients with Lung Adenocarcinoma: a Predictive Marker for EGFR Mutation

Reliability of Using Circulating Tumor Cells for Detecting Epidermal Growth Factor Receptor Mutation Status in Advanced Non-Small-cell Lung Cancer Patients: a Meta-Analysis and Systematic Review

The study of detection EGFR gene mutation in non-small cell lung cancer tissue and matched pleural effusion

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.

EGFR mutations in malignant pleural effusions from lung cancer

Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients

Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion

Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis